Your browser is no longer supported. Please, upgrade your browser.
INSM Insmed Incorporated daily Stock Chart
INSM [NASD]
Insmed Incorporated
Index- P/E- EPS (ttm)-4.28 Insider Own1.20% Shs Outstand90.55M Perf Week-1.73%
Market Cap2.16B Forward P/E- EPS next Y-2.56 Insider Trans-4.84% Shs Float83.58M Perf Month-17.90%
Income-329.90M PEG- EPS next Q-0.88 Inst Own95.60% Short Float13.68% Perf Quarter-19.65%
Sales31.70M P/S67.98 EPS this Y-45.70% Inst Trans-0.44% Short Ratio12.91 Perf Half Y50.44%
Book/sh1.86 P/B12.80 EPS next Y29.50% ROA-51.00% Target Price42.78 Perf Year-17.36%
Cash/sh4.64 P/C5.13 EPS next 5Y- ROE-130.10% 52W Range11.31 - 33.13 Perf YTD81.40%
Dividend- P/FCF- EPS past 5Y-21.30% ROI-59.00% 52W High-28.16% Beta2.88
Dividend %- Quick Ratio4.70 Sales past 5Y-3.10% Gross Margin79.30% 52W Low110.43% ATR1.27
Employees373 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)39.17 Volatility5.26% 4.72%
OptionableYes Debt/Eq2.23 EPS Q/Q-6.90% Profit Margin- Rel Volume0.76 Prev Close24.71
ShortableYes LT Debt/Eq2.23 EarningsMay 07 BMO Payout- Avg Volume885.78K Price23.80
Recom1.80 SMA20-5.65% SMA50-15.88% SMA2004.53% Volume691,145 Change-3.68%
Apr-09-19Reiterated H.C. Wainwright Buy $43 → $52
Feb-15-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $40
Jan-17-19Upgrade Goldman Neutral → Buy
Jan-02-19Initiated Canaccord Genuity Buy $20
Aug-06-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18Initiated Goldman Neutral $32
Apr-23-18Upgrade Credit Suisse Neutral → Outperform
Mar-21-18Initiated Morgan Stanley Overweight $39
Jan-18-18Initiated Credit Suisse Neutral $31
Sep-05-17Reiterated Evercore ISI Outperform $28 → $40
Aug-17-17Initiated Evercore ISI Outperform $28
Jul-11-17Initiated Robert W. Baird Outperform $23
Mar-15-16Initiated Stifel Buy $23
Nov-09-15Downgrade UBS Buy → Neutral $35 → $18
Oct-06-15Reiterated H.C. Wainwright Buy $30 → $35
Jun-09-15Initiated Citigroup Neutral $27
Mar-26-14Reiterated HC Wainwright Buy $25 → $30
Jan-06-14Reiterated UBS Buy $17.50 → $31
Nov-11-13Initiated HC Wainwright Buy $25
Jun-19-13Initiated UBS Buy $17.50
Jun-11-19 04:38PM  Is Insmed Incorporated (INSM) A Good Stock To Buy? Insider Monkey
Jun-06-19 08:00AM  Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
Jun-04-19 04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jun-02-19 01:45AM  Edited Transcript of INSM earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-24-19 11:27AM  Insmed Announces Closing of Public Offering of Common Stock PR Newswire
May-22-19 10:53AM  What Did Insmed Incorporated's (NASDAQ:INSM) CEO Take Home Last Year? Simply Wall St.
07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 08:56PM  Insmed Announces Pricing of Public Offering of Common Stock PR Newswire -5.91%
07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga
May-20-19 04:05PM  Insmed Announces Proposed Public Offering of Common Stock PR Newswire
04:01PM  New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease PR Newswire
May-07-19 11:24PM  Insmed (INSM) Q1 2019 Earnings Call Transcript Motley Fool -12.21%
08:55AM  Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:52AM  Insmed: 1Q Earnings Snapshot Associated Press
07:30AM  Insmed Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
May-02-19 01:55PM  Did Hedge Funds Drop The Ball On Insmed Incorporated (INSM) ? Insider Monkey
May-01-19 07:20AM  Top Ranked Momentum Stocks to Buy for May 1st Zacks
Apr-30-19 08:00AM  Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019 PR Newswire
Apr-16-19 10:29AM  Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM) Simply Wall St.
Apr-09-19 04:36PM  Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio PR Newswire
Apr-08-19 05:00AM  Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch PR Newswire
Apr-02-19 04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Apr-01-19 04:05PM  Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference PR Newswire
08:00AM  Insmed to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire
Mar-27-19 04:15PM  Insmed Announces Management Changes PR Newswire
Mar-04-19 04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Feb-26-19 02:11PM  Edited Transcript of INSM earnings conference call or presentation 22-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-22-19 12:16PM  Insmed Inc (INSM) Q4 2018 Earnings Conference Call Transcript Motley Fool +11.42%
10:05AM  Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:54AM  Insmed: 4Q Earnings Snapshot Associated Press
07:30AM  Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
Feb-20-19 08:00AM  Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference PR Newswire
Feb-15-19 08:00AM  Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019 PR Newswire
Feb-13-19 09:29AM  Is Insmed Incorporateds (NASDAQ:INSM) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Feb-07-19 07:50AM  Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-04-19 04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Jan-25-19 08:56AM  Options Traders Expect Huge Moves in Insmed (INSM) Stock Zacks +5.62%
Jan-16-19 10:16AM  Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-12-19 12:00PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-11-19 07:46AM  The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference Motley Fool
Jan-07-19 07:49PM  Here's Why Insmed Rocketed 43% Higher on Monday Motley Fool +43.23%
04:05PM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
01:56PM  Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology ETF Trends
Jan-04-19 04:35PM  Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter MarketWatch +6.76%
04:05PM  Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019 PR Newswire
Dec-18-18 11:54PM  Is Insmed Incorporated (INSM) A Good Stock To Buy? Insider Monkey
Dec-04-18 08:30AM  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -8.85%
Nov-14-18 11:35AM  Healthcare Stocks with Turnaround Potential ACCESSWIRE
Nov-08-18 08:50AM  Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A Fundamental Analysis, Key Performance Indications GlobeNewswire
08:30AM  Insmed Announces Changes to its Board of Directors GlobeNewswire
Nov-06-18 08:30AM  Insmed to Present at Three November Conferences GlobeNewswire
Nov-05-18 11:09PM  Edited Transcript of INSM earnings conference call or presentation 30-Oct-18 12:30pm GMT Thomson Reuters StreetEvents +5.21%
Nov-02-18 07:15PM  Insmed Inc (INSM) President & CEO William Lewis Bought $249,630 of Shares GuruFocus.com
Oct-30-18 07:45AM  Insmed: 3Q Earnings Snapshot Associated Press -8.07%
07:30AM  Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-23-18 08:30AM  Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018 GlobeNewswire
Oct-16-18 02:46PM  Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.64%
Oct-11-18 08:30AM  Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension) GlobeNewswire
Oct-04-18 04:30PM  Insmed Extends Patent Protection in Japan to 2033 GlobeNewswire
Oct-01-18 06:01PM  What Analysts Have To Say About Insmed Following Arikayce Approval Benzinga -22.16%
12:45PM  Here's Why Insmed Slumped Lower Today Motley Fool
11:46AM  Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce Zacks
08:00AM  Insmed to Present at Two October Conferences GlobeNewswire
Sep-28-18 06:36PM  Insmed's treatment-resistant lung disease drug gets FDA approval Reuters -5.25%
05:58PM  Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options GlobeNewswire
05:45PM  Insmed's treatment-resistant lung disease drug gets FDA approval Reuters
Sep-24-18 08:54AM  Is the Options Market Predicting a Spike in Insmed (INSM) Stock? Zacks +5.54%
Sep-17-18 08:00AM  Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine GlobeNewswire
Aug-17-18 07:35AM  Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Aug-13-18 01:26PM  The Week Ahead: Nvidia, Retailer Earnings In Focus Benzinga
Aug-08-18 08:15AM  The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga -8.95%
Aug-07-18 05:30PM  FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmeds ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options GlobeNewswire
Aug-06-18 03:30PM  The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal Benzinga -6.81%
Aug-04-18 03:19AM  Edited Transcript of INSM earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:58AM  Insmed: 2Q Earnings Snapshot Associated Press +13.36%
07:30AM  Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-26-18 08:00AM  Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018 GlobeNewswire
Jul-13-18 07:30AM  Free Technical Research on Insmed and Three More Biotech Equities ACCESSWIRE
Jun-15-18 08:00AM  Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC GlobeNewswire -5.41%
Jun-07-18 08:00AM  Insmed to Present at Three June Conferences GlobeNewswire
May-30-18 07:50AM  Recent Analysis Shows Northwest Natural Gas, Brooks Automation, Insmed, Host Hotels & Resorts, Prospect Capital, and Inphi Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
May-25-18 08:30AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed ACCESSWIRE
May-23-18 08:15AM  Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing Benzinga
May-22-18 05:15PM  Insmed Announces Presentations at the American Thoracic Society 2018 International Conference GlobeNewswire
May-18-18 07:50AM  Blog Exposure - FDA Accepted for Review Insmeds Marketing Application for ALIS in NTM Lung Disease Caused by MAC ACCESSWIRE
May-17-18 04:05PM  Insmed Appoints Leo Lee to its Board of Directors GlobeNewswire
May-16-18 08:00AM  Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC GlobeNewswire
May-09-18 03:52AM  Edited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 08:43PM  Insmed Incorporated (NASDAQ:INSM): Is Breakeven Near? Simply Wall St.
May-03-18 08:30AM  Today's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals ACCESSWIRE -5.11%
May-02-18 09:18AM  Insmed: 1Q Earnings Snapshot Associated Press +9.50%
07:30AM  Insmed Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-01-18 08:00AM  Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-25-18 08:00AM  Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018 GlobeNewswire
Apr-23-18 12:20PM  Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade Benzinga +10.76%
Apr-10-18 07:42AM  Insmed (INSM): Moving Average Crossover Alert Zacks +6.34%
Apr-05-18 08:00AM  Research Report Identifies Brown & Brown, CorVel, Pacific Ethanol, HomeTrust Bancshares, FORTERRA INC, and Insmed with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-03-18 08:00AM  Todays Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed ACCESSWIRE
07:20AM  Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease ACCESSWIRE
Mar-29-18 08:00AM  Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC GlobeNewswire
Insmed Incorporated, a global biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schaeffer Orlov S NicoleChief People Strategy OfficerJun 06Option Exercise6.9612,00083,52036,350Jun 10 04:05 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerJun 06Sale23.2412,000278,83924,350Jun 10 04:05 PM
HAYDEN DONALD J JRDirectorApr 09Option Exercise3.036,28619,04768,483Apr 11 04:06 PM
HAYDEN DONALD J JRDirectorApr 09Sale32.996,286207,37562,197Apr 11 04:06 PM
ALTOMARI ALFREDDirectorFeb 26Sale30.005,500165,00025,942Feb 27 04:07 PM
HAYDEN DONALD J JRDirectorFeb 22Option Exercise3.0314,90045,14777,097Feb 26 04:07 PM
HAYDEN DONALD J JRDirectorFeb 22Sale28.0814,900418,39262,197Feb 26 04:07 PM
HAYDEN DONALD J JRDirectorFeb 15Option Exercise3.0310030362,297Feb 27 04:08 PM
ALTOMARI ALFREDDirectorFeb 15Sale27.505,500151,25031,442Feb 20 04:05 PM
HAYDEN DONALD J JRDirectorFeb 15Sale27.901002,79062,197Feb 27 04:08 PM
ALTOMARI ALFREDDirectorFeb 05Sale25.005,500137,50036,942Feb 07 04:07 PM
ALTOMARI ALFREDDirectorJan 10Sale22.505,500123,75042,442Jan 14 04:15 PM
SHAROKY MELVIN MDDirectorNov 12Buy15.598,795137,11020,000Nov 13 04:03 PM
SHAROKY MELVIN MDDirectorNov 09Buy16.3411,205183,10211,205Nov 13 04:03 PM
ENGELSEN STEINAR JDirectorNov 01Buy15.7916,085253,993281,303Nov 02 04:07 PM
Adsett RogerChief Commercial OfficerNov 01Buy15.973,00047,90718,594Nov 02 04:07 PM
Lewis WilliamPresident & CEONov 01Buy15.9015,700249,600151,247Nov 02 04:06 PM